The Department of Health and Human Services on April 19 announced a $1.1 billion public-private partnership to help maintain access to COVID-19 vaccines and treatment for uninsured individuals through pharmacies, health centers and state and local public health departments after the federal government no longer pays for or distributes them, a transition expected this fall. 

Under the HHS Bridge Access Program, the Centers for Disease Control and Prevention will purchase and distribute COVID-19 vaccines to local health departments and participating health centers, and contract with pharmacies to continue offering COVID-19 vaccines and designated treatments with no out-of-pocket costs to uninsured individuals. The contracts also will allow uninsured individuals to receive access to certain COVID-19 treatments, including the drugs Paxlovid and Lagevrio, from participating pharmacies with no out-of-pocket costs, HHS said.

HHS said it has identified COVID-19 supplemental funds to support the program through 2024.

“As a more permanent measure, both the FY 2023 and FY 2024 President’s Budgets proposed the Vaccines for Adults program, which would be modeled after the successful Vaccines for Children program that already covers recommended immunizations for children, including vaccinations for COVID-19, with no cost-sharing,” the agency said.

Related News Articles

#HealthCareInnovation Blog
In the fall of 2021, two years into the COVID-19 pandemic in the U.S., nearly 80% of adults said they had heard “at least one of eight different false…
Headline
Summertime is right around the corner and AHA’s new social media toolkit promotes COVID-19 vaccination and boosters as a means for keeping kids active and…
Headline
The Food and Drug Administration April 28 authorized a fourth Pfizer COVID-19 bivalent vaccine dose at least one month after the third dose for certain…
Headline
In a study of adults hospitalized between February 2022 and February 2023, when the omicron variant predominated, monovalent mRNA vaccination was 76%…
Headline
The Centers for Disease Control and Prevention April 19 recommended a second Moderna or Pfizer COVID-19 bivalent vaccine dose for adults aged 65 and older…
Headline
The Food and Drug Administration authorized using a single dose of the Moderna or Pfizer bivalent COVID-19 vaccine for primary vaccination as well as…